Dapagliflozin for the treatment of type 2 diabetes: a review of the literature

References

• International Diabetes Federation (IDF) IDF Diabetes Atlas 6th ed Brussels IDF 2013 Available from: http://www.idf.org/diabetesatlas Accessed August 18, 2014
   Google Scholar
• Stratton IM Adler AI Neil HA Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study BMJ 2000 321 7258 405 412 10938048
   PubMed Web of Science ®Google Scholar
• Gregg EW Li Y Wang J Changes in diabetes-related complications in the United States, 1990–2010 N Engl J Med 2014 370 16 1514 1523 24738668
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence (NICE) Diabetes in Pregnancy: Management of Diabetes and its Complications from Preconception to the Postnatal Period London NICE 2008 Available from: http://www.nice.org.uk/guidance/CG63 Accessed August 18, 2014
   Google Scholar
• National Institute for Health and Care Excellence (NICE) Type 2 Diabetes: The Management of Type 2 Diabetes London NICE 2009 Available from: http://www.nice.org.uk/Guidance/CG87 Accessed August 18, 2014
   Google Scholar
• International Diabetes Federation (IDF) Working Group Global Guideline for Type 2 Diabetes Brussels IDF 2012 Available from: http://www.idf.org/global-guideline-type-2-diabetes-2012 Accessed August 18, 2014
   Google Scholar
• Scottish Intercollegiate Guidelines Network (SIGN) Management of Diabetes: A National Clinical Guideline Edinburgh SIGN 2010 Available from: http://www.sign.ac.uk/guidelines/fulltext/116 Accessed August 18, 2014
   Google Scholar
• Garber AJ Abrahamson MJ Barzilay JI AACE comprehensive diabetes management algorithm 2013 Endocr Pract 2013 19 2 327 336 23598536
   PubMed Web of Science ®Google Scholar
• Inzucchi SE Bergenstal RM Buse JB Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) Diabetes Care 2012 35 6 1364 1379 22517736
   PubMed Web of Science ®Google Scholar
• Canadian Diabetes Association Clinical Practice Guidelines Expert Committee Imran SA Rabasa-Lhoret R Ross S Targets for glycemic control Can J Diabetes 2013 37 Suppl 1 S31 S34 24070959
   PubMed Web of Science ®Google Scholar
• Cheung BM Ong KL Cherny SS Sham PC Tso AW Lam KSL Diabetes prevalence and therapeutic target achievement in the United States, 1999 to 2006 Am J Med 2009 122 5 443 453 19375554
   PubMed Web of Science ®Google Scholar
• Grant RW Devita NG Singer DE Meigs JB Polypharmacy and medication adherence in patients with type 2 diabetes Diabetes Care 2003 26 5 1408 1412 12716797
   PubMed Web of Science ®Google Scholar
• Holman RR Assessing the potential for alpha-glucosidase inhibitors in prediabetic states Diabetes Res Clin Pract 1998 40 Suppl S21 S25 9740498
   PubMed Web of Science ®Google Scholar
• Prentki M Nolan CJ Islet beta cell failure in type 2 diabetes J Clin Invest 2006 116 7 1802 1812 16823478
   PubMed Web of Science ®Google Scholar
• Matthews DR Cull CA Stratton IM Holman RR Turner RC UKPDS 26: Sulphonylurea failure in non-insulin-dependent diabetic patients over six years. UK Prospective Diabetes Study (UKPDS) Group Diabet Med 1998 15 4 297 303 9585394
   PubMed Web of Science ®Google Scholar
• Diabetes UK Diabetes and obesity rates soar 2009 Available from: http://www.diabetes.org.uk/About_us/News_Landing_Page/Diabetes-and-obesity-rates-soar Accessed September 2, 2014
   Google Scholar
• Kahn SE Hull RL Utzschneider KM Mechanisms linking obesity to insulin resistance and type 2 diabetes Nature 2006 444 7121 840 846 17167471
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration FDA approves Farxiga to treat type 2 diabetes [press release] Silver Spring, MD FDA 2014 [January 8]. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm380829 Accessed October 13, 2014
   Google Scholar
• European Medicines Agency European Medicines Agency recommends authorisation of novel treatment for type-2 diabetes [press release] London EMA 2012 [April 20]. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2012/04/news_detail_001499.jsp&mid=WC0b01ac058004d5c12012 Accessed October 13, 2014
   Google Scholar
• AstraZeneca Forxiga^® receives regulatory approval in Japan for the treatment of type 2 diabetes [press release] London AstraZeneca 2014 [March 24]. Available from: http://www.astrazeneca.com/Media/Press-releases/Article/20140324--forxiga-japan-approval Accessed October 13, 2014
   Google Scholar
• Scottish Medicines Consortium Archived: dapagliflozin (Forxiga) 2013 Available from: http://www.scottishmedicines.org.uk/SMC_Advice/Advice/799_12_dapagliflozin_Forxiga/dapagliflozin_Forxiga Accessed October 13, 2014
   Google Scholar
• Arant BSJr Developmental patterns of renal functional maturation compared in the human neonate J Pediatr 1978 92 5 705 712 641617
   PubMed Web of Science ®Google Scholar
• Alpern RJ Moe O Caplan M Seldin DW Seldin and Giebisch’s The Kidney: Physiology and Pathophysiology Oxford Academic 2012
   Google Scholar
• Wright EM Hirayama BA Loo DF Active sugar transport in health and disease J Intern Med 2007 261 1 32 43 17222166
   PubMed Web of Science ®Google Scholar
• Wright EM Renal Na(+)-glucose cotransporters Am J Physiol Renal Physiol 2001 280 1 F10 F18 11133510
   PubMed Web of Science ®Google Scholar
• Hediger MA Rhoads DB Molecular physiology of sodium-glucose cotransporters Physiol Rev 1994 74 4 993 1026 7938229
   PubMed Web of Science ®Google Scholar
• Bakris GL Fonseca VA Sharma K Wright EM Renal sodium-glucose transport: role in diabetes mellitus and potential clinical implications Kidney Int 2009 75 12 1272 1277 19357717
   PubMed Web of Science ®Google Scholar
• Wright EM Loo DD Hirayama BA Biology of human sodium glucose transporters Physiol Rev 2011 91 2 733 794 21527736
   PubMed Web of Science ®Google Scholar
• Oliva RV Bakris GL Blood pressure effects of sodium-glucose co-transport 2 (SGLT2) inhibitors J Am Soc Hypertens 2014 8 5 330 339 24631482
   PubMed Web of Science ®Google Scholar
• Chao EC Henry RR SGLT2 inhibition – a novel strategy for diabetes treatment Nat Rev Drug Discov 2010 9 7 551 559 20508640
   PubMed Web of Science ®Google Scholar
• Jung CH Jang JE Park JY A novel therapeutic agent for type 2 diabetes mellitus: SGLT2 inhibitor Diabetes Metab J 2014 38 4 261 273 25215272
   PubMedGoogle Scholar
• Santer R Calado J Familial renal glucosuria and SGLT2: from a Mendelian trait to a therapeutic target Clin J Am Soc Nephrol 2010 5 1 133 141 19965550
   PubMed Web of Science ®Google Scholar
• McKusick VA Fanconi-Bickel syndrome 2006 Available from: http://www.omim.org/entry/227810 Accessed August 18, 2014
   Google Scholar
• Ehrenkranz JR Lewis NG Kahn CR Roth J Phlorizin: a review Diabetes Metab Res Rev 2005 21 1 31 38 15624123
   PubMed Web of Science ®Google Scholar
• Anderson SL Marrs JC Dapagliflozin for the treatment of type 2 diabetes Ann Pharmacother 2012 46 4 590 598 22433611
   PubMed Web of Science ®Google Scholar
• Bonner C Popescu I Queniat G The glucose transporter SGLT 2 is expressed in human pancreatic alpha cells and is required for proper control of glucagon secretion in type 2 diabetes Diabetes 2014 63 Suppl 1 A101
   Google Scholar
• Merovci A Solis-Herrera C Daniele G Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production J Clin Invest 2014 124 2 509 514 24463448
   PubMed Web of Science ®Google Scholar
• Electronic Medicines Compendium Forxiga 5 mg and 10 mg film coated tablets 2014 Available from: http://www.medicines.org.uk/emc/medicine/27188/SPC/Forxiga+5+mg+%26+10+mg+film+coated+tablets Accessed August 18, 2014
   Google Scholar
• Kasichayanula S Liu X Lacreta F Griffen SC Boulton DW Clinical pharmacokinetics and pharmacodynamics of dapagliflozin, a selective inhibitor of sodium-glucose co-transporter type 2 Clin Pharmacokinet 2014 53 1 17 27 24105299
   PubMed Web of Science ®Google Scholar
• Kasichayanula S Liu X Zhang W Effect of a high-fat meal on the pharmacokinetics of dapagliflozin, a selective SGLT2 inhibitor, in healthy subjects Diabetes Obes Metab 2011 13 8 770 773 21435141
   PubMed Web of Science ®Google Scholar
• Kasichayanula S Liu X Pe Benito M The influence of kidney function on dapagliflozin exposure, metabolism and pharmacodynamics in healthy subjects and in patients with type 2 diabetes mellitus Br J Clin Pharmacol 2013 76 3 432 444 23210765
   PubMed Web of Science ®Google Scholar
• Yang L Li H Li H Pharmacokinetic and pharmacodynamic properties of single- and multiple-dose of dapagliflozin, a selective inhibitor of SGLT2, in healthy Chinese subjects Clin Ther 2013 35 8 1211.e2 1222.e2 23910664
   PubMed Web of Science ®Google Scholar
• Kasichayanula S Chang M Hasegawa M Pharmacokinetics and pharmacodynamics of dapagliflozin, a novel selective inhibitor of sodium-glucose co-transporter type 2, in Japanese subjects without and with type 2 diabetes mellitus Diabetes Obes Metab 2011 13 4 357 365 21226818
   PubMed Web of Science ®Google Scholar
• Komoroski B Vachharajani N Feng Y Li L Kornhauser D Pfister M Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus Clin Pharmacol Ther 2009 85 5 513 519 19129749
   PubMed Web of Science ®Google Scholar
• Komoroski B Vachharajani N Boulton D Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects Clin Pharmacol Ther 2009 85 5 520 526 19129748
   PubMed Web of Science ®Google Scholar
• Chino Y Samukawa Y Sakai S SGLT2 inhibitor lowers serum uric acid through alteration of uric acid transport activity in renal tubule by increased glycosuria Biopharm Drug Dispos 2014 35 7 391 404 25044127
   PubMed Web of Science ®Google Scholar
• Aylsworth A Dean Z VanNorman C Nkemdirim Okere A Dapagliflozin for the treatment of type 2 diabetes mellitus Ann Pharmacother 2014 48 9 1202 1208 24951310
   PubMed Web of Science ®Google Scholar
• Zhang L Feng Y List J Kasichayanula S Pfister M Dapagliflozin treatment in patients with different stages of type 2 diabetes mellitus: effects on glycaemic control and body weight Diabetes Obes Metab 2010 12 6 510 516 20518806
   PubMed Web of Science ®Google Scholar
• Ferrannini E Ramos SJ Salsali A Tang W List JF Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial Diabetes Care 2010 33 10 2217 2224 20566676
   PubMed Web of Science ®Google Scholar
• Bailey CJ Iqbal N T’Joen C List JF Dapagliflozin monotherapy in drug-naive patients with diabetes: a randomized-controlled trial of low-dose range Diabetes Obes Metab 2012 14 10 951 959 22776824
   PubMed Web of Science ®Google Scholar
• Henry RR Murray AV Marmolejo MH Hennicken D Ptaszynska A List JF Dapagliflozin, metformin XR, or both: initial pharmacotherapy for type 2 diabetes, a randomised controlled trial Int J Clin Pract 2012 66 5 446 456 22413962
   PubMed Web of Science ®Google Scholar
• Kaku K Inoue S Matsuoka O Efficacy and safety of dapagliflozin as a monotherapy for type 2 diabetes mellitus in Japanese patients with inadequate glycaemic control: a phase II multicentre, randomized, double-blind, placebo-controlled trial Diabetes Obes Metab 2013 15 5 432 440 23194084
   PubMed Web of Science ®Google Scholar
• Ji L Ma J Li H Dapagliflozin as monotherapy in drug-naive Asian patients with type 2 diabetes mellitus: a randomized, blinded, prospective phase III study Clin Ther 2014 36 1 84.e9 100.e9 24378206
   PubMed Web of Science ®Google Scholar
• List JF Woo V Morales E Tang W Fiedorek FT Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes Diabetes Care 2009 32 4 650 657 19114612
   PubMed Web of Science ®Google Scholar
• Bailey CJ Gross JL Pieters A Bastien A List JF Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial Lancet 2010 375 9733 2223 2233 20609968
   PubMed Web of Science ®Google Scholar
• Bailey CJ Gross JL Hennicken D Iqbal N Mansfield TA List JF Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial BMC Med 2013 11 43 23425012
   PubMed Web of Science ®Google Scholar
• Mudaliar S Henry RR Boden G Changes in insulin sensitivity and insulin secretion with the sodium glucose cotransporter 2 inhibitor dapagliflozin Diabetes Technol Ther 2014 16 3 137 144 24237386
   PubMed Web of Science ®Google Scholar
• Nauck MA Del Prato S Meier JJ Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial Diabetes Care 2011 34 9 2015 2022 21816980
   PubMed Web of Science ®Google Scholar
• Nauck MA Del Prato S Duran-Garcia S Durability of glycaemic efficacy over 2 years with dapagliflozin versus glipizide as add-on therapies in patients whose type 2 diabetes mellitus was inadequately controlled with metformin Diabetes Obes Metab 2014 16 11 1111 1120 24919526
   PubMed Web of Science ®Google Scholar
• Langkilde AM Nauck MA Prato SD Durability of dapagliflozin vs glipizide as add-on therapies in T2DM inadequately controlled on metformin: 4-year data Diabetologia 2013 56 1 S374
   Google Scholar
• Strojek K Yoon KH Hruba V Elze M Langkilde AM Parikh S Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial Diabetes Obes Metab 2011 13 10 928 938 21672123
   PubMed Web of Science ®Google Scholar
• Strojek K Yoon KH Hruba V Sugg J Langkilde AM Parikh S Dapagliflozin added to glimepiride in patients with type 2 diabetes mellitus sustains glycemic control and weight loss over 48 weeks: a randomized, double-blind, parallel-group, placebo-controlled trial Diabetes Ther 2014 5 1 267 283 24920277
   PubMed Web of Science ®Google Scholar
• Rosenstock J Vico M Wei L Salsali A List JF Effects of dapagliflozin, an SGLT2 inhibitor, on HbA(1c), body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy Diabetes Care 2012 35 7 1473 1478 22446170
   PubMed Web of Science ®Google Scholar
• Jabbour SA Hardy E Sugg J Parikh S Study G Dapagliflozin is effective as add-on therapy to sitagliptin with or without metformin: a 24-week, multicenter, randomized, double-blind, placebo-controlled study Diabetes Care 2014 37 3 740 750 24144654
   PubMed Web of Science ®Google Scholar
• Tatarkiewicz K Polizzi C Villescaz C Combined antidiabetic benefits of exenatide and dapagliflozin in diabetic mice Diabetes Obes Metab 2014 16 4 376 380 24251534
   PubMed Web of Science ®Google Scholar
• Jabbour S Hardy E de Bruin TW Dapagliflozin helps reduce HbA_1c and body weight in patients with type 2 diabetes as part of triple combination therapy: a subanalysis of 4 clinical studies Poster presented at: European Association for the Study of Diabetes Meeting September 23–27, 2013 Barcelona, Spain
   Google Scholar
• Rosenstock J Hansen L Zee PY Cook W Hirshberg B Iqbal N Dual add-on therapy in poorly controlled type 2 diabetes on metformin: randomized, double-blind trial of saxagliptin + dapagliflozin vs saxagliptin and dapagliflozin alone Diabetes 2014 63 Suppl 1A LB32 LB33
   Google Scholar
• Matthaei S Bowering K Rohwedder K Grohl A Johnsson E Improvement in glycemic control and reduction in body weight over 52 weeks with dapagliflozin as add-on therapy to metformin plus sulfonylurea Diabetes 2014 63 Suppl 1 A70 A71
   Google Scholar
• Wilding JP Norwood P T’Joen C Bastien A List JF Fiedorek FT A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: applicability of a novel insulin-independent treatment Diabetes Care 2009 32 9 1656 1662 19528367
   PubMed Web of Science ®Google Scholar
• Wilding JP Woo V Soler NG Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial Ann Intern Med 2012 156 6 405 415 22431673
   PubMed Web of Science ®Google Scholar
• Wilding JP Woo V Rohwedder K Sugg J Parikh S Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years Diabetes Obes Metab 2014 16 2 124 136 23911013
   PubMed Web of Science ®Google Scholar
• Sun YN Zhou Y Chen X Che WS Leung SW The efficacy of dapagliflozin combined with hypoglycaemic drugs in treating type 2 diabetes mellitus: meta-analysis of randomised controlled trials BMJ Open 2014 4 4 e004619
   PubMed Web of Science ®Google Scholar
• Zhang M Zhang L Wu B Song H An Z Li S Dapagliflozin treatment for type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials Diabetes Metab Res Rev 2014 30 3 204 221 24115369
   PubMed Web of Science ®Google Scholar
• Goring S Hawkins N Wygant G Dapagliflozin compared with other oral anti-diabetes treatments when added to metformin monotherapy: a systematic review and network meta-analysis Diabetes Obes Metab 2014 16 5 433 442 24237939
   PubMed Web of Science ®Google Scholar
• Musso G Gambino R Cassader M Pagano G A novel approach to control hyperglycemia in type 2 diabetes: sodium glucose co-transport (SGLT) inhibitors: systematic review and meta-analysis of randomized trials Ann Med 2012 44 4 375 393 21495788
   PubMed Web of Science ®Google Scholar
• Vasilakou D Karagiannis T Athanasiadou E Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis Ann Intern Med 2013 159 4 262 274 24026259
   PubMed Web of Science ®Google Scholar
• Bolinder J Ljunggren O Kullberg J Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin J Clin Endocrinol Metab 2012 97 3 1020 1031 22238392
   PubMed Web of Science ®Google Scholar
• Bolinder J Ljunggren O Johansson L Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin Diabetes Obes Metab 2014 16 2 159 169 23906445
   PubMed Web of Science ®Google Scholar
• Lambers Heerspink HJ de Zeeuw D Wie L Leslie B List J Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes Diabetes Obes Metab 2013 15 9 853 862 23668478
   PubMed Web of Science ®Google Scholar
• Weber MA Mansfield T List JF Ptaszynska A Dapagliflozin lowered ambulatory blood pressure in patients with T2DM and hypertension inadequately controlled by a renin-angiotensin system blocker with or without another agent Diabetes 2014 63 Suppl 1 A266
   Google Scholar
• Sjöström D Ptaszynska A List JF Johnsson E Dapagliflozin lowers blood pressure in patients with type 2 diabetes Diabetes 2014 63 Suppl 1 A613
   Google Scholar
• Grandy S Hashemi M Langkilde AM Parikh S Sjöström CD Changes in weight loss-related quality of life among type 2 diabetes mellitus patients treated with dapagliflozin Diabetes Obes Metab 2014 16 7 645 650 24443876
   PubMed Web of Science ®Google Scholar
• Grandy S Ryden A Sugg JE Rohwedder K Weight-related quality of life and treatment satisfaction among type 2 diabetes mellitus patients treated with dapagliflozin in triple-therapy regimen Diabetes 2014 63 Suppl 1 A204 A205
   Google Scholar
• Johnsson KM Ptaszynska A Schmitz B Sugg J Parikh SJ List JF Vulvovaginitis and balanitis in patients with diabetes treated with dapagliflozin J Diabetes Complications 2013 27 5 479 484 23806570
   PubMed Web of Science ®Google Scholar
• Johnsson KM Ptaszynska A Schmitz B Sugg J Parikh SJ List JF Urinary tract infections in patients with diabetes treated with dapagliflozin J Diabetes Complications 2013 27 5 473 478 23849632
   PubMed Web of Science ®Google Scholar
• Thomson SC Rieg T Miracle C Acute and chronic effects of SGLT2 blockade on glomerular and tubular function in the early diabetic rat Am J Physiol Regul Integr Comp Physiol 2012 302 1 R75 R83 21940401
   PubMed Web of Science ®Google Scholar
• Kohan DE Fioretto P Tang W List JF Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control Kidney Int 2014 85 4 962 971 24067431
   PubMed Web of Science ®Google Scholar
• Ptaszynska A Mansfield T Johnsson E Parikh SJ Yavin Y List JF Long-term renal safety with dapagliflozin treatment Diabetes 2014 63 Suppl 1 A267
   Google Scholar
• US Food and Drug Administration Background document: dapagli-flozin (BMS-512148, NDA 202293) 2013 Available from: http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/endocrinologicandmetabolicdrugsadvisorycommittee/ucm378079.pdf Accessed August 18, 2014
   Google Scholar
• Reilly TP Graziano MJ Janovitz EB Carcinogenicity risk assessment supports the chronic safety of dapagliflozin, an inhibitor of sodium-glucose co-transporter 2, in the treatment of type 2 diabetes mellitus Diabetes Ther 2014 5 1 73 96 24474422
   PubMed Web of Science ®Google Scholar
• European Medicines Agency Forxiga (dapagliflozin) 2014 Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002322/human_med_001546.jsp&mid=WC0b01ac058001d124 Accessed August 18, 2014
   Google Scholar
• European Medicines Agency Xigduo (dapagliflozin/metformin) 2014 Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002672/human_med_001721.jsp&mid=WC0b01ac058001d124 Accessed August 18, 2014
   Google Scholar
• Mansfield T Fioretto P Ptaszynska A Dapagliflozin is safe and well tolerated in older patients with T2DM Diabetes 2014 63 Suppl 1 A71
   Google Scholar
• Erbey JR Silberman C Lydick E Prevalence of abnormal serum alanine aminotransferase levels in obese patients and patients with type 2 diabetes Am J Med 2000 109 7 588 590 11063962
   PubMed Web of Science ®Google Scholar
• Harris EH Elevated liver function tests in type 2 diabetes Clin Diabetes 2005 23 3 115 119
   Google Scholar
• Kasichayanula S Liu X Zhang W Pfister M LaCreta FP Boulton DW Influence of hepatic impairment on the pharmacokinetics and safety profile of dapagliflozin: an open-label, parallel-group, single-dose study Clin Ther 2011 33 11 1798 1808 22030444
   PubMed Web of Science ®Google Scholar
• Leiter LA Cefalu WT de Bruin TW Gause-Nilsson I Sugg J Parikh SJ Dapagliflozin added to usual care in individuals with type 2 diabetes mellitus with preexisting cardiovascular disease: a 24-week, multicenter, randomized, double-blind, placebo-controlled study with a 28-week extension J Am Geriatr Soc 2014 62 7 1252 1262 24890683
   PubMed Web of Science ®Google Scholar
• Gause-Nilsson I Bruin TW Sugg JE Parikh SJ Johnsson E Leiter LA Two-year efficacy and safety of dapagliflozin for T2DM patients with a history of cardiovascular disease Diabetes 2014 63 Suppl 1 A271
   Google Scholar
• Dziuba J Alperin P Racketa J Modeling effects of SGLT-2 inhibitor dapagliflozin treatment versus standard diabetes therapy on cardiovascular and microvascular outcomes Diabetes Obes Metab 2014 16 7 628 635 24443793
   PubMed Web of Science ®Google Scholar
• Kaku K Inoue S Matsuoka O Efficacy and safety of dapagliflozin as a monotherapy for type 2 diabetes mellitus in Japanese patients with inadequate glycaemic control: a phase II multicentre, randomized, double-blind, placebo-controlled trial Diabetes Obes Metab 2013 15 5 432 440 23194084
   PubMed Web of Science ®Google Scholar
• Henry RR Rosenstock J Chalamandaris AG Kasichayanula S Bogle A Griffen SC Exploring the potential of dapagliflozin in type 1 diabetes: phase 2A pilot study Diabetes 2013 62 Suppl 1A LB70
   Google Scholar
• Cherney DZ Perkins BA Soleymanlou N Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus Circulation 2014 129 5 587 597 24334175
   PubMed Web of Science ®Google Scholar
• Kasichayanula S Chang M Liu X Lack of pharmacokinetic interactions between dapagliflozin and simvastatin, valsartan, warfarin, or digoxin Adv Ther 2012 29 2 163 177 22271159
   PubMed Web of Science ®Google Scholar
• Kasichayanula S Liu X Griffen SC Lacreta FP Boulton DW Effects of rifampin and mefenamic acid on the pharmacokinetics and pharmacodynamics of dapagliflozin Diabetes Obes Metab 2013 15 3 280 283 23061428
   PubMed Web of Science ®Google Scholar
• van Haalen HG Pompen M Bergenheim K McEwan P Townsend R Roudaut M Cost effectiveness of adding dapagliflozin to insulin for the treatment of type 2 diabetes mellitus in the Netherlands Clin Drug Investig 2014 34 2 135 146
   PubMed Web of Science ®Google Scholar
• Sabale U Ekman M Granström O Bergenheim K McEwan P Cost-effectiveness of dapagliflozin (Forxiga) added to metformin compared with sulfonylurea added to metformin in type 2 diabetes in the Nordic countries Prim Care Diabetes Epub 2014 5 16
   Web of Science ®Google Scholar
• National Institute for Health and Care Excellence (NICE) Dapagliflozin in Combination Therapy for Treating Type 2 Diabetes London NICE 2013 Available from: http://www.nice.org.uk/Guidance/TA288 Accessed August 18, 2014
   Google Scholar
• Kurosaki E Ogasawara H Ipragliflozin and other sodium-glucose cotransporter-2 (SGLT2) inhibitors in the treatment of type 2 diabetes: preclinical and clinical data Pharmacol Ther 2013 139 1 51 59 23563279
   PubMed Web of Science ®Google Scholar
• Poole RM Dungo RT Ipragliflozin: first global approval Drugs 2014 74 5 611 617 24668021
   PubMed Web of Science ®Google Scholar
• Poole RM Prossler JE Tofogliflozin: first global approval Drugs 2014 74 8 939 944 24848755
   PubMed Web of Science ®Google Scholar
• Markham A Elkinson S Luseogliflozin: first global approval Drugs 2014 74 8 945 950 24848756
   PubMed Web of Science ®Google Scholar
• Diamant M Morsink LM SGLT2 inhibitors for diabetes: turning symptoms into therapy Lancet 2013 382 9896 917 918 23850056
   PubMed Web of Science ®Google Scholar
• Kapur A O’Connor-Semmes R Hussey EK First human dose-escalation study with remogliflozin etabonate, a selective inhibitor of the sodium-glucose transporter 2 (SGLT2), in healthy subjects and in subjects with type 2 diabetes mellitus BMC Pharmacol Toxicol 2013 14 26 23668634
   PubMed Web of Science ®Google Scholar
• Yale JF Bakris G Cariou B Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease Diabetes Obes Metab 2013 15 5 463 473 23464594
   PubMed Web of Science ®Google Scholar
• Barnett AH Mithal A Manassie J Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial Lancet Diabetes Endocrinol 2014 2 5 369 384 24795251
   PubMed Web of Science ®Google Scholar